NZ564369A - 5-[2-propyloxy-5(1-methyl-2-pyrrolidinylethylamidosulphonyl)phenyl]-1-methyl-propyl-1,6-dihydro-7H-pyrazolo(4,3-d)pyrimidin-7-one for the prevention and treatment of liver diseases - Google Patents

5-[2-propyloxy-5(1-methyl-2-pyrrolidinylethylamidosulphonyl)phenyl]-1-methyl-propyl-1,6-dihydro-7H-pyrazolo(4,3-d)pyrimidin-7-one for the prevention and treatment of liver diseases

Info

Publication number
NZ564369A
NZ564369A NZ564369A NZ56436905A NZ564369A NZ 564369 A NZ564369 A NZ 564369A NZ 564369 A NZ564369 A NZ 564369A NZ 56436905 A NZ56436905 A NZ 56436905A NZ 564369 A NZ564369 A NZ 564369A
Authority
NZ
New Zealand
Prior art keywords
methyl
portal
liver
hepatic
propyl
Prior art date
Application number
NZ564369A
Other languages
English (en)
Inventor
Seul Min Choi
Byoung Ok Ahn
Moohi Yoo
Original Assignee
Dong A Pharm Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dong A Pharm Co Ltd filed Critical Dong A Pharm Co Ltd
Publication of NZ564369A publication Critical patent/NZ564369A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NZ564369A 2005-06-10 2005-10-21 5-[2-propyloxy-5(1-methyl-2-pyrrolidinylethylamidosulphonyl)phenyl]-1-methyl-propyl-1,6-dihydro-7H-pyrazolo(4,3-d)pyrimidin-7-one for the prevention and treatment of liver diseases NZ564369A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20050050033 2005-06-10
PCT/KR2005/003526 WO2006132460A1 (en) 2005-06-10 2005-10-21 Agent for the prevention and treatment of liver diseases containing pyrazolopyrimidine derivative

Publications (1)

Publication Number Publication Date
NZ564369A true NZ564369A (en) 2010-03-26

Family

ID=37498629

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ564369A NZ564369A (en) 2005-06-10 2005-10-21 5-[2-propyloxy-5(1-methyl-2-pyrrolidinylethylamidosulphonyl)phenyl]-1-methyl-propyl-1,6-dihydro-7H-pyrazolo(4,3-d)pyrimidin-7-one for the prevention and treatment of liver diseases

Country Status (22)

Country Link
US (1) US8796286B2 (da)
EP (1) EP1888074B1 (da)
JP (1) JP4879977B2 (da)
KR (1) KR100914445B1 (da)
CN (1) CN101193636B (da)
AT (1) ATE537832T1 (da)
AU (1) AU2005332719B2 (da)
BR (1) BRPI0520209A2 (da)
CA (1) CA2611638C (da)
CY (1) CY1112637T1 (da)
DK (1) DK1888074T3 (da)
ES (1) ES2376628T3 (da)
HK (1) HK1119596A1 (da)
IL (1) IL187678A (da)
MX (1) MX2007015365A (da)
NO (1) NO20076053L (da)
NZ (1) NZ564369A (da)
PT (1) PT1888074E (da)
RU (1) RU2369392C2 (da)
UA (1) UA86528C2 (da)
WO (1) WO2006132460A1 (da)
ZA (1) ZA200800180B (da)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100322917A1 (en) * 2006-12-28 2010-12-23 Insect Biotech Co., Ltd. Pharmaceutical composition containing arazyme for the prevention of liver dysfunction
WO2010118367A2 (en) * 2009-04-10 2010-10-14 Progenics Pharmaceuticals, Inc. Antiviral pyrimidines
KR20130026504A (ko) * 2010-07-14 2013-03-13 큠버랜드 에멀징 테크놀로지스 아이앤씨 트롬복산-a2 수용체 길항제를 이용한 간신증후군 및 간성뇌증의 치료방법
EP2873017B1 (en) 2012-07-11 2021-09-01 University of Mississippi Medical Center Method for the detection and staging of liver fibrosis from image acquired data
ES2848348T3 (es) 2014-05-16 2021-08-06 Cumberland Pharmaceuticals Inc Composiciones y métodos de tratamiento con ifetroban de la fibrosis cardíaca
KR102448406B1 (ko) 2015-06-30 2022-09-27 큠버랜드 파마슈티컬즈 인코포레이티드 Ａｅｒｄ/천식에서 트롬복산 수용체 길항제
AU2017263462B2 (en) 2016-05-11 2021-05-13 Cumberland Pharmaceuticals, Inc. Compositions and methods of treating muscular dystrophy with thromboxane-A2 receptor antagonists
CN110833556A (zh) * 2018-08-15 2020-02-25 广西梧州制药（集团）股份有限公司 吡唑并嘧啶衍生物在治疗肝纤维化的用途
CN113493459B (zh) * 2020-04-07 2022-12-13 广州白云山医药集团股份有限公司白云山制药总厂 Pde5抑制剂化合物及其制备方法和应用
CA3229274A1 (en) * 2021-08-13 2023-02-16 Mezzion Pharma Co., Ltd. Methods and compositions for treating fibrotic liver conditions, using udenafil compositions

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100353014B1 (ko) * 1998-11-11 2002-09-18 동아제약 주식회사 발기부전 치료에 효과를 갖는 피라졸로피리미디논 화합물
KR100377782B1 (ko) 2000-06-23 2003-03-29 동아제약 주식회사 발기부전 치료에 효과를 갖는 피라졸로피리미디논화합물의 제조방법
US20030216407A1 (en) * 2002-01-31 2003-11-20 Pfizer Inc. Use of PDE5 inhibitors in the treatment of scarring
GB0202254D0 (en) 2002-01-31 2002-03-20 Pfizer Ltd Prevention of scarring
EP1336602A1 (en) * 2002-02-13 2003-08-20 Giovanni Scaramuzzino Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases
GB0214784D0 (en) 2002-06-26 2002-08-07 Pfizer Ltd Novel combination
WO2004037183A2 (en) 2002-10-22 2004-05-06 Harbor-Ucla Research And Education Institute Phosphodiester inhibitors and nitric oxide modulators for treating peyronie’s disease, arteriosclerosis and other fibrotic diseases
WO2004108662A1 (ja) 2003-05-15 2004-12-16 Kumiai Chemical Industry Co., Ltd. フェニルスルホニルカーバメイト誘導体及び農園芸用植物病害防除剤
DE10325813B4 (de) * 2003-06-06 2007-12-20 Universitätsklinikum Freiburg Prophylaxe und/oder Therapie bei der portalen Hypertonie
JP2006527257A (ja) * 2003-06-10 2006-11-30 ファイザー・インク 月経困難症の治療用のｐｄｅ阻害剤及びバソプレッシン受容体アンタゴニストを含んでなる療法組合せ
DE102005001989A1 (de) * 2005-01-15 2006-07-20 Bayer Healthcare Ag Intravenöse Formulierungen von PDE-Inhibitoren

Also Published As

Publication number Publication date
CA2611638A1 (en) 2006-12-14
JP2008543748A (ja) 2008-12-04
IL187678A (en) 2013-04-30
EP1888074A4 (en) 2010-06-23
KR100914445B1 (ko) 2009-08-28
RU2369392C2 (ru) 2009-10-10
RU2007149474A (ru) 2009-07-20
KR20060128605A (ko) 2006-12-14
NO20076053L (no) 2008-02-27
JP4879977B2 (ja) 2012-02-22
WO2006132460A1 (en) 2006-12-14
IL187678A0 (en) 2008-11-03
AU2005332719A1 (en) 2006-12-14
HK1119596A1 (en) 2009-03-13
EP1888074B1 (en) 2011-12-21
AU2005332719B2 (en) 2010-05-13
PT1888074E (pt) 2012-03-01
EP1888074A1 (en) 2008-02-20
CY1112637T1 (el) 2016-02-10
MX2007015365A (es) 2008-02-12
ATE537832T1 (de) 2012-01-15
US20080207646A1 (en) 2008-08-28
ZA200800180B (en) 2009-01-28
CN101193636A (zh) 2008-06-04
DK1888074T3 (da) 2012-01-23
UA86528C2 (uk) 2009-04-27
CA2611638C (en) 2010-08-24
US8796286B2 (en) 2014-08-05
BRPI0520209A2 (pt) 2009-04-22
CN101193636B (zh) 2011-12-28
ES2376628T3 (es) 2012-03-15

Similar Documents

Publication Publication Date Title
AU2005332719B2 (en) Agent for the prevention and treatment of liver diseases containing pyrazolopyrimidine derivative
TWI336702B (en) Benzimidazole derivative and use thereof
JP4698681B2 (ja) アミノピリミジン類の化合物及びその塩の調製方法と薬物の用途
US8772326B2 (en) Methods and compositions of small molecule modulators of hepatocyte growth factor (scatter factor) activity
UA80756C2 (en) Antineoplastic combinations of rapomicine and interferon alfa (?) in the treatment of neoplasms
CN110049764A (zh) 用于治疗肾脏疾病或病症的联苯磺酰胺化合物
US20190328734A1 (en) Use of Sanglifehrin Macrocyclic Analogues as Anticancer Compounds
AU2004283413B2 (en) Alfavbeta3 and alfavbeta6 integrin antagonists as antifibrotic agents
CN101146541A (zh) 用于治疗中枢神经系统疾病的方法和组合物
JP2022062115A (ja) ｓＧＣ刺激剤のリンプロドラッグ
TWI248931B (en) Pharmaceutical composition for regeneration of cirrhotic liver
EP1452176A1 (en) Insulin resistance improving agents
CN1968686B (zh) 脒腙盐、组合物、制备方法和使用方法
WO2001021166A1 (en) Treatment and prevention of hepatic disorders
CA2813719A1 (en) Methods of use of small molecule modulators of hepatocyte growth factor (scatter factor) activity
Li et al. Injectable, drug-eluting nanocrystals prevent fibrosis and stricture formation in vivo
US8791117B2 (en) Cyclic glycyl-2-allyl proline improves cognitive performance in impaired animals
JP2014515026A (ja) アカデシン誘導体、それを含有する製剤および組成物、その治療目的での使用、ならびにその合成法
US20230277447A1 (en) Targeted release rifaximin compositions
KR100860326B1 (ko) 에포틸론 ｂ를 함유하는 혈관재협착 예방 및 치료제
WO1998044916A1 (fr) Medicaments de prevention ou de traitement de la recto-colite hemorragique et/ou de la maladie de crohn
WO2004073717A1 (ja) 血管新生促進剤

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 OCT 2016 BY CPA GLOBAL

Effective date: 20151012

LAPS Patent lapsed